<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1000083763474443&amp;ev=PageView&amp;noscript=1">

SmartTRAK Life Sciences News and Analysis Blog

4 min read

Q319 Market Recap: US Surgical Matrices: Tepid Growth

12/12/19 3:48 PM

Q319 Surgical Matrices RecapThe US Surgical Matrices Market grew tepidly in Q319,  up +1.2% YoY,  down from its +3.5% growth in Q219. 

The overall US Surgical Matrices market had minimal growth for the quarter at +1.2% YoY, a decline from Q219. The Breast segment contracted -1.5% YoY and a 34.7% share of the entire Surgical Matrices market. The Hernia Repair market continued its modest growth at +2.6% YoY and a 65.3% share of the US Surgical Matrices Market in Q319.

In Q319, Allergan’s hold on the Breast Matrices segment slipped further due to supply chain issues with its AlloDerm ADM, but the Company maintained its leadership of the Surgical Matrices market a 32.3% share. BD continued its growth in their biosynthetic hernia matrices business and maintained No. 2 market position, with revenues of ...

Among the many topics covered in the complete, comprehensive Q319 US Surgical Matrices Market Recap* are:

  • Q319 Surgical Matrices Market Overview
  • US Breast Matrices: Allergan’s Struggle Continues
  • US Hernia Repair Matrices Market: Modest Growth Again
  • Other Q319 events in the US Surgical Matrices Market

The US Breast Matrices market, comprised of allografts, xenografts and biosynthetics, declined -1.5% YoY to $XXX Blurred. This was driven primarily by Allergan’s continuing problems with its AlloDerm supply chain. In Q319, allografts captured 94.2% with a -1.9% YoY decline...

Read the complete, comprehensive Q319 US Surgical Matrices Market Recap including news, data, charts, company revenues and analysis*...

*The entire unedited article can only be viewed by SmartTRAK subscribers to this module. For information on how to subscribe, please click the button below.

Request SmartTRAK Subscription Info


Topics: Wound Care

Doug Devens
Written by Doug Devens

20 years of diverse medical device experience, including leading companies 3M, Coloplast and Boston Scientific, along with emerging companies. Leadership experience in product development, including championing the process for voice of customer and concept feedback sessions with key thought leaders.

    Recent Articles